Most hematological neoplasms associated with 11q23 chromosomal rearrangement have been cases of acute lymphoblastic or acute myeloid leukemia. Although cases of myelodysplastic syndrome (MDS) are a minority, these syndromes should also be recognized as part of the spectrum of hematological disorders associated with 11q23 rearrangement. In this series of 550 patients with such rearrangement there were 28 (5.1%) who presented with MDS. A further five patients had a history of MDS but had evolved to AML by the time cytogenetic analysis was first undertaken. There were thus a total of 33 patients (6.0%) with an 11q23 abnormality whose initial presentation was as MDS. Of these 33 patients, a quarter (seven patients) were cases of secondary (therapy-related) MDS. Complex karyotypes and other poor prognosis chromosomal abnormalities such as −7 and 7q− were common and were not confined to secondary cases. The likelihood of presentation as MDS differed between different cytogenetic categories. The 28 patients in whom cytogenetic analysis was performed at presentation as MDS showed a wide age distribution, from 1 to 82 years; there were four children, two of 1 year of age. All FAB types of MDS were represented. Median survival was only 19.1 months. Leukemic transformation occurred in five patients including one case of transformation to a biphenotypic M5a/T-lineage acute leukemia.
Introduction
Hematological malignancies reported in association with karyotypic abnormalities with an 11q23 breakpoint have mainly been cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). The myelodysplastic syndromes (MDS) are a less commonly recognized association. We therefore analyzed clinical, hematological and cytogenetic features of cases of MDS with an abnormality of 11q23 submitted to the EU Concerted Action Workshop.
Materials and methods
Materials and methods were as previously described. 1 In brief, karyotypes were reviewed, hematological and clinical data were analyzed and, in a minority of patients, microscopic slides were reviewed. The diagnosis and further classification of MDS was according to the criteria suggested by the FrenchAmerican-British (FAB) Co-operative Group. 2, 3 All the kary- 
Results
Twenty-eight of 550 patients (5.1%) presented with MDS and had a chromosomal rearrangement with an 11q23 breakpoint detected on cytogenetic analysis (Table 1) . A further five patients had already evolved to AML when cytogenetic analysis was first performed and an 11q23 abnormality was detected. However these patients had a history of preceding MDS of 2 to 10 months duration and may well have had the same cytogenetic abnormality during that phase of the disease. A further patient presented with MDS and monosomy 7 with t(9;11)(p22;q23) being found only when M5 AML developed; this case will not be further considered here since she did not have a myelodysplastic presentation with an 11q23 abnormality. It is likely that a total of 33 patients (6.0%) had an initial presentation of MDS associated with an 11q23 abnormality. Of these 33 patients, a quarter (seven patients) were cases of secondary (therapy-related) MDS. In addition, a patient with del(11)(q21q23) with a history of polycythemia rubra vera had received intermittent busulphan therapy over a number of years and may also have had secondary MDS. However acute leukemia as part of the natural history of polycythemia rubra vera cannot be excluded. The 28 patients presenting as MDS had an age range of 1 to 82 years (median 59). Four of the five with t(9;11)(p22;q23) were children, including two who were aged 1 year. All other patients were adults. Thirteen patients were male and 15 were female. When these 28 patients were categorized according to the FAB classification, there were 13 cases of refractory anemia (RA), one of refractory anemia with ring sideroblasts (RARS), four of refractory anemia with excess of blasts (RAEB), five of refractory anemia with excess of blasts in transformation (RAEBt) and two of chronic myelomonocytic leukemia (CMML) (see Figure 1) . Three cases were unclassifiable as insufficient data were available. In comparison with MDS in general, RA was over-represented and RARS was underrepresented.
The prognosis was generally poor, particularly since half the cases presented with RA which usually has a median survival of many years. Although only six of the 28 cases presenting as MDS suffered transformation to acute leukemia the median survival was only 19.1 months (Figure 2 ). Transformation was to AML M5a in one case and to a biphenotypic (AML M5a/Tlineage acute leukemia) in another. In the other four cases the nature of the acute transformation was not known.
The likelihood of presentation as MDS varied considerably between cytogenetic categories (Table 2) . No cases were seen among patients with t(6;11)(q27;q23), t(10;11)(p12;q23) or t(11;19)(q23;p13.3). MDS was most prevalent among the patients with del(11)(q) and in the group of patients with miscellaneous abnormalities. Of 57 patients with del(11)(q), 12 (5)(q13q33),der(7)t(7;13)(p22;q1),-9,der (11) add (11) 
Figure 1
Bone marrow aspirate from a patient with t(11;19)(q23;p13.1) and chronic myelomonocytic leukemia showing granulocytes, monocytes and their precursors (patient 520).
(21%) presented with MDS. Further analysis suggested that this was a heterogeneous group with regard to the likelihood of an MDS presentation. The patients with MDS included three of seven patients with del(11)(q13q23), two of seven patients with del(11)(q14q23), two of five patients with del(11)(q21q23) and five of 28 patients with del(11)(q23). Among the patients with miscellaneous abnormalities there were also obvious differences in the probability of a presentation as MDS between the different cytogenetic groups. There were only three patients with t(2;11)(p21;q23) in the entire group of which two presented with MDS while the third had evolved to AML when cytogenetic analysis was first carried out but had a previous history of MDS of 10 months duration. Similarly, two of three patients with inv(11)(p15q23) and one of two patients with dup(11)(q14q23) presented with MDS. The patient with MDS and t(11;21)(q23;q11) represented the only patient with that abnormality. MDS was less prevalent in patients with t(1;11)(q21;q23) (one of six patients), inv(11)(p14q23) (one of three patients) and add(11)(q23) (one of 18 patients). There were other miscellaneous cytogenetic groups in which no cases of MDS were observed. For example, there were none among the 13 cases with a 17q12-25 breakpoint (of which seven had t(11;17)(q23;q21) and six had t(11;17)(q23;q25), nor among the seven patients with t(1;11)(p32;q23).
Figure 2
Survival curve for the 26 patients, presenting with MDS and found to have a chromosomal rearrangement with an 11q23 breakpoint, for whom survival data were available. The full karyotypes of the 28 patients presenting with MDS are shown in Table 1 . Twelve of the 28 patients had partial loss of chromosome 11 of which seven were described as interstitial and five as terminal deletions. Lack of MLL involvement was demonstrated by FISH in all four cases investigated. FISH showed only one MLL signal in two cases (ie MLL was deleted) while a third case showed two MLL signals (ie MLL was not rearranged). In one further case Southern blotting showed MLL to be germline. Among the 16 cases with other abnormalities of 11q23 MLL was shown to be rearranged in six of eight cases investigated. MLL was not rearranged in one case with t(2;11)(p21;q23) nor in one with inv(11)(p15q23). Twenty of 28 patients had deletions or unbalanced translocation leading to loss of chromosomal material. Eleven patients had 5q−, 7q− or −7 in addition to an 11q23 abnormality. Seven patients had a complex clone (with more than two karyotypic abnormalities).
There have been at least 66 previous reports of MDS associated with 11q23 breakpoints, representing at least 64 cases, which have been described in some detail. The characteristics of these cases are summarized in Table 3 . In addition there have been a number of cases described in less detail. Pedersen and Kerndrup 51 reported two cases with del(11)(q23) and either RA or RARS with bone marrow monocytosis. Bernasconi and colleagues 52 reported 38 cases comprising eight cases with t(9;11)(p22;q23) with RAEBt (six cases) or CMML (two cases); one case with t(11;17)(q23;q22) and RAEBt; 21 cases with del(11)(q14q23) with RA (eight cases), RAEB (nine cases) or RAEBt (four cases); and eight cases with del(11)(q23) with RAEB (three cases) or RAEBt (five cases).
Discussion
Although only a minority of patients present in this manner, MDS should be recognized as one of the hematological manifestations of 11q23 rearrangement. Including our 28 cases there have now been a total of at least 92 such cases reported. All FAB categories of MDS are seen. Interestingly, despite the prevalence of M4 and M5 AML (acute myelomonocytic and acute monocytic/monoblastic leukemia) among cases of acute leukemia there is no similar predominance of chronic myelomonocytic leukemia among the cases of MDS. In this series of patients refractory anemia was the subtype most often observed, and this was also the case for previously described cases. Unusually for MDS, but in keeping with what is seen with acute leukemia in association with 11q23 abnormalities, four of the patients were children. Of previously reported cases, 12 were children, including two children with t(9;11) and four with t(11;16). Men and women were equally represented. Prognosis was poor, despite the low rate of transformation to acute leukemia and the fact that half the patients Table 3 Previously reported cases of myelodysplastic syndrome associated with an abnormality of 11q23 in our series had refractory anemia, usually associated with a good prognosis. Prognosis may be related in part to the frequency of complex karyotypes and to the occurrence of other cytogenetic abnormalities usually associated with a poor prognosis in MDS. MDS does not show an equal prevalence among different cytogenetic subgroups, emphasizing that not only MLL but also the partner gene has a role in determining the phenotype of the hematological neoplasms which develop in association with 11q23 rearrangements. The group of patients with del(11)(q23) show marked differences from some of the better characterized subtypes involving 11q23, including the highest observed prevalence of MDS. Whether MLL rearrangement is in fact as common in this group as in other well characterized Exposed to radioactive iodine. 3 Exposed to organic solvents and benzene. 4 It appears likely that these are different reports on the same case. 5 It appears likely that these are different reports on the same case. 6 Previous aplastic anemia.
abnormalities or whether other oncogenic mechanisms are operating in some patients remains to be established. Kobayashi and colleagues 26 have demonstrated that abnormalities characterized cytogenetically as terminal deletions may, on FISH, be identified as translocations, whereas interstitial translocations are mainly found to delete a common region proximal to MLL and without rearrangement of the MLL gene. 35 It may be that in these latter cases the oncogenic mechanism is deletion of a cancer suppressor gene proximal to MLL.
